Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis
Autore:
Tran, GT; Carter, N; Hodgkinson, SJ;
Indirizzi:
Univ New S Wales, Liverpool Hosp, Dept Med, Liverpool, NSW 2170, AustraliaUniv New S Wales Liverpool NSW Australia 2170 erpool, NSW 2170, Australia
Titolo Testata:
INTERNATIONAL IMMUNOPHARMACOLOGY
fascicolo: 9-10, volume: 1, anno: 2001,
pagine: 1709 - 1723
SICI:
1567-5769(200109)1:9-10<1709:MMTARF>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
CENTRAL-NERVOUS-SYSTEM; CYCLOSPORIN-A TREATMENT; ACTIVE HEYMANN NEPHRITIS; CD4+ T-CELLS; LEWIS RAT; LONG-TERM; MONOCLONAL-ANTIBODIES; ALLOGRAFT-REJECTION; CYTOKINE PRODUCTION; ADOPTIVE TRANSFER;
Keywords:
antibody; cytokine; EAE; mycophenolate mofetil; therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
63
Recensione:
Indirizzi per estratti:
Indirizzo: Hodgkinson, SJ Univ New S Wales, Liverpool Hosp, Dept Med, Liverpool, NSW 2170, Australia Univ New S Wales Liverpool NSW Australia 2170 0, Australia
Citazione:
G.T. Tran et al., "Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis", INT IMMUNO, 1(9-10), 2001, pp. 1709-1723

Abstract

Mycophenolate mofetil (MM) acts through its metabolite mycophenolic acid to inhibit inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for purine synthesis in lymphocytes. Oral treatment with MM from the day ofimmunization for 2 weeks significantly delayed both the development of active experimental allergic encephalomyelitis (EAE) in Lewis rats and reducedthe antibody response to myelin basic protein (MBP). MM did not deplete T and B cells, nor did it prevent induction of Th1 or Th2 cytokine in the regional nodes. Treatment of EAE with MM at the onset of clinical symptoms resulted in more rapid recovery from EAE than in control or cyclosporin A (CsA)-treated. MM-treated rats had less infiltration of T cells, B cells, macrophages and dendritic cells into brainstems than either the control or CsA-treated. MM-treated brainstems also had lower level of mRNA for Thl (IL-2, IL-12R ss2, IFN-gamma), Th2 (IL-4. IL-10) cytokines and TNF-alpha and TGF-sscompared to that in CsA and controls groups. This study shows MM was superior to CsA in the treatment of EAE and acted by reducing the inflammatory infiltrate, not by suppression of Ig response or by promotion of regulatory cells such as Th2 or Th3. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 14:38:48